Expression of sFas and sFasL in breast cancer and their clinical significance

JIANG Ying,JIANG Hong-Wei,HUANG Guo-Min

DOI: https://doi.org/10.3969/j.issn.1005-9202.2007.05.031

2007-01-01

Abstract:Objective To study the changes and clinical significance of serum soluble Fas (sFas) and FasL (sFasL) levels in patients with breast cancer.Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of serum sFas and sFasL in 85 patients with breast cancer, 24 patients with benign breast tumors and 30 patients with non breast disease and to analyze the correlation both of them to the clinical pathological parameters of breast cancer and the changes both of them by clinical treatments. Immunohistochemical S-P method was used to detect the expression of sFas and sFasL in 85 cases of breast cancer tissues and 30 cases of the normal breast tissues.Results Serum sFas and sFasL levels in breast cancer group were significantly higher than those of the other two groups, those of stage Ⅲ and Ⅳ were significantly higher than those of stageⅠandⅡ, those after treatments were remarkably lower than those before treatments (all P<0.05). No significant correlations were found between sFas and sFasL and the other clinical pathological parameters of breast cancer. Serum sFas and sFasL levels of the two control groups showed no significant difference (P>0.05). In normal breast tissues, carcinoma in situ and invasive cancer, the positive rates of sFas and sFasL were 40.0%, 52.9%, 69.2% and 0.0%, 100.0%, 100.0%. Conclusions Serum sFas and sFasL may serve as novel tumor markers for breast cancer, both of them may be related to immune escape.